Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum [Yahoo! Finance]
PAVmed Inc. (PAVM)
US:NASDAQ Investor Relations:
ir.pavm.com
Company Research
Source: Yahoo! Finance
the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, being held November 20, 2025 in New York City. Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. (PRNewsfoto/Lucid Diagnostics) Dennis McGrath, Lucid's Chief Financial Officer, will be available for one-on-one meetings with investors. To schedule a meeting, please contact your Canaccord Genuity representative. About Lucid Diagnostics Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also kn
Show less
Read more
Impact Snapshot
Event Time:
PAVM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PAVM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PAVM alerts
High impacting PAVmed Inc. news events
Weekly update
A roundup of the hottest topics
PAVM
News
- PAVmed (NASDAQ:PAVM) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- PAVmed Inc. (PAVM) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- PAVmed Provides Business Update and Reports Third Quarter 2025 Financial ResultsPR Newswire
- PAVmed Inc (PAVM) Q3 2025 Earnings Report Preview: What to Expect [Yahoo! Finance]Yahoo! Finance
- PAVmed Non-GAAP EPS of -$0.10, revenue of $1.21M [Seeking Alpha]Seeking Alpha
PAVM
Earnings
- 11/13/25 - Beat
PAVM
Analyst Actions
- 10/6/25 - Ascendiant Capital
PAVM
Sec Filings
- 11/13/25 - Form 8-K
- 11/12/25 - Form 10-Q
- 10/31/25 - Form DEF
- PAVM's page on the SEC website